Recruiting

A Novel Target Delineation Scheme Based on RTOG(Radiation Therapy Oncology Group) and EORTC(European Organisation for Research and Treatment of Cancer) Guidelines Impact on Survival Time and Radiotherapy Complications in High-grade Glioma Patients: a Single-center Randomized Single-blind Clinical Trial

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

reduced target volume

+ EORTC (European organisation for research and treatment of cancer) target volume

Radiation
Who is being recruted

Glioma+7

+ Neoplasms

+ Neoplasms by Histologic Type

From 18 to 65 Years
+19 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
Study Start: February 2024
See protocol details

Summary

Principal SponsorZhujiang Hospital
Study ContactYujing Tan, Doctor
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: February 18, 2024

Actual date on which the first participant was enrolled.

This study seeks to find out if a new method for planning radiation therapy can help extend the time before high-grade glioma, a type of aggressive brain tumor, gets worse. It also looks to see if this new method can lower the chances of patients experiencing side effects from the radiation treatment. High-grade glioma is challenging to treat, so finding better ways to manage it could significantly improve patients' quality of life and survival time. Participants who are part of this study will undergo surgery and then, 4-6 weeks later, receive radiation therapy. For the trial group, the new method of planning radiation therapy will be used, while the control group will receive a standard method as per guidelines from a European cancer research organization. Both groups will also take a chemotherapy drug called Temozolomide to help enhance treatment effectiveness during and after radiation therapy. The study will monitor how long patients remain free from cancer progression and assess any radiation-related complications to determine the effectiveness and safety of the new radiation planning approach.

Official TitleA Novel Target Delineation Scheme Based on RTOG(Radiation Therapy Oncology Group) and EORTC(European Organisation for Research and Treatment of Cancer) Guidelines Impact on Survival Time and Radiotherapy Complications in High-grade Glioma Patients: a Single-center Randomized Single-blind Clinical Trial
NCT06215495
Principal SponsorZhujiang Hospital
Study ContactYujing Tan, Doctor
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

88 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 65 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

GliomaNeoplasmsNeoplasms by Histologic TypeNeoplasms, Germ Cell and EmbryonalNeoplasms, Glandular and EpithelialNeoplasms, Nerve TissueRadiation InjuriesWounds and InjuriesNeuroectodermal TumorsNeoplasms, Neuroepithelial

Criteria

9 inclusion criteria required to participate
High-grade glioma (2021 WHO grade III or IV)
Age between 18-65 years old, Karnofsky performance status (KPS) score ≥ 70
result of pregnancy test being negative within 7 days before enrollment, only applicable to women with reproductive potential
The patient voluntarily joined this study and signed an informed consent form
Show More Criteria
10 exclusion criteria prevent from participating
Low-grade glioma(2021 WHO grade I or II)
had or having other type of malignant cancers
not having been performed gross total resection of tumor
Severe active comorbidities, systemic diseases or other serious comorbidities that would render the patient unsuitable for participation in this study or seriously interfere with the appropriate evaluation of the safety and toxicity of the prescribed regimen in the judgment of the investigator, including but not limited to persistent or active infections, symptomatic congestive heart failure, unstable angina pectoris, arrhythmia, or mental illness；
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental

Group II

Active Comparator

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

southern medical university affiliated Zhujiang Hospital

Guangzhou, ChinaOpen southern medical university affiliated Zhujiang Hospital in Google Maps
Recruiting
One Study Center